How is the therapeutic effect of brigatinib evaluated?

Brigatinib is a new type of tyrosine kinase inhibitor that has received widespread attention in the treatment of non-small cell lung cancer (NSCLC) in recent years.

ALTAThe clinical trial is a multi-center, randomized, double-blind, controlled study designed to evaluate the efficacy and safety of brigatinib in patients with non-small cell lung cancer. This trial included a large number of patients with advanced ALK positive non-small cell lung cancer and further verified the clinical application value of brigatinib by comparing the efficacy of brigatinib with traditional chemotherapy drugs.

InALTA clinical trials, brigatinib showed significant efficacy. First, in terms of the primary endpoint of progression-free survival (PFS), brigatinib significantly prolonged the patients' PFS compared with the control group. This means that after patients receive brigatinib treatment, the rate of disease progression is significantly slowed down and the survival time is effectively extended.

In terms of objective response rate (ORR), brigatinib also showed high efficacy. After receiving brigatinib treatment, many patients' tumors have significantly shrunk or even disappeared, and their symptoms have been significantly improved. These positive treatment effects result in longer survival and better quality of life for patients.

Brigatinib has also shown significant efficacy in controlling brain metastases. Because brigatinib can cross the blood-brain barrier better, it has also achieved good efficacy in patients with brain metastases. This is particularly important for patients with advanced non-small cell lung cancer, as brain metastasis is one of the common complications in these patients.

In terms of safety, brigatinib also performed relatively well. Although patients may experience some adverse reactions during the use of brigatinib, such as nausea, vomiting, diarrhea, etc., these are mild to moderate reactions and can be alleviated with appropriate symptomatic treatment. In addition, the incidence of serious adverse reactions is relatively low and can be effectively controlled under the guidance of a doctor.

InALTA clinical trials, brigatinib and first-generationALK inhibitor crizotinib was compared. The results showed that brigatinib was significantly better than crizotinib in terms of therapeutic effect. Brigatinib has shown better efficacy in terms of progression-free survival, objective response rate, and brain metastasis control. This result provides strong support for the application of brigatinib in the treatment of lung cancer.

Although brigatinib has shown significant efficacy and good safety in clinical trials, the following points still need to be paid attention to in practical applications: first, doctors need to fully understand the patient's specific situation and formulate a personalized treatment plan; secondly, during use, the patient's response and condition changes need to be closely monitored, and the treatment plan should be adjusted in a timely manner; finally, adverse reactions that occur need to be dealt with in a timely manner and the drug dose must be adjusted to ensure patient safety.

In summary, data analysis based on the ALTA clinical trial shows that brigatinib has good efficacy and safety in the treatment of non-small cell lung cancer. The drug can effectively prolong the progression-free survival of patients and improve the objective response rate, and has also shown significant effects in the control of brain metastases.

References:

https://www.ahdbonline.com/issues/2018/april-2018-vol-11-ninth-annual-payers-guide/alunbrig-brigatinib-approved-for-metastatic-nsclc-with-alk-mutation